Blueprint Medicines Corporation
Blueprint Medicines Corporation (BPMC) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · BPMC · as of Jun 30, 2025
Ownership Breakdown
381
Institutional Holders
▲ 10 vs Q1
$8.24B
Total Inst. Value
▲ $2.13B vs Q1
64.58M
Shares Outstanding
freeFloat 92.91%
64.32M
13F Shares Held
▼ 4.80M vs Q1
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
BPMC largest shareholders · institutional ownership
Q2 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
VANGUARD GROUP INC pharmaceutical preparations | 6.42M | 10.09% | 10.09% | $822.48B | Aug 11, 2025 | ▼ 223.9K |
BLACKROCK, INC. pharmaceutical preparations | 6.12M | 9.62% | 9.62% | $784.26B | Aug 12, 2025 | ▼ 592.3K |
PENTWATER CAPITAL MANAGEMENT LP pharmaceutical preparations | 3.90M | 6.13% | 6.13% | $499.90B | Aug 14, 2025 | NEW |
STATE STREET CORP pharmaceutical preparations | 2.23M | 3.51% | 3.51% | $285.97B | Aug 14, 2025 | ▼ 453.1K |
UBS GROUP AG pharmaceutical preparations | 2.17M | 3.41% | 3.41% | $277.77B | Aug 14, 2025 | ▲ 1.95M |
FIL LTD pharmaceutical preparations | 1.76M | 2.77% | 2.77% | $225.53B | Aug 14, 2025 | NEW |
UBS OCONNOR LLC pharmaceutical preparations | 1.71M | 2.69% | 2.69% | $219.65B | Aug 14, 2025 | ▲ 1.70M |
BARCLAYS PLC pharmaceutical preparations | 1.56M | 2.45% | 2.45% | $199.57B | Feb 27, 2026 | ▲ 1.43M |
GEODE CAPITAL MANAGEMENT, LLC pharmaceutical preparations | 1.54M | 2.42% | 2.42% | $197.55B | Aug 8, 2025 | ▲ 18.4K |
PRICE T ROWE ASSOCIATES INC /MD/ pharmaceutical preparations | 1.46M | 2.30% | 2.30% | $187.78B | Aug 14, 2025 | ▼ 3.95M |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q2 2025 vs prior quarter
Q2 2025
14
Increased
+9.73M shares13
New Positions
first time holders23
Decreased
−16.93M shares0
Sold Out
fully exitedNet shares change (top 50)
7.20M
+9.73M / −16.93M
Net new holders
+4
13 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
BPMC insider trading · insider activity
Source: SEC Form 4
2
Buy transactions
20
Sell transactions
0.10
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Landsittel Michael Chief Financial Officer | Jul 17, 2025 | Award | 21,353 | — | — | 94.3K | Form 4 ↗ |
Landsittel Michael Chief Financial Officer | Jul 17, 2025 | D-Return | 51,102 | — | — | 43.2K | Form 4 ↗ |
Landsittel Michael Chief Financial Officer | Jul 17, 2025 | D-Return | 25,000 | $61.31 | $1.53M | 0 | Form 4 ↗ |
Landsittel Michael Chief Financial Officer | Jul 17, 2025 | D-Return | 25,000 | $43.15 | $1.08M | 0 | Form 4 ↗ |
Landsittel Michael Chief Financial Officer | Jul 17, 2025 | D-Return | 10,000 | $15.01 | $150.1K | 0 | Form 4 ↗ |
Landsittel Michael Chief Financial Officer | Jul 17, 2025 | U-Tender | 43,175 | — | — | 0 | Form 4 ↗ |
Landsittel Michael Chief Financial Officer | Jul 17, 2025 | D-Return | 19,500 | $86.60 | $1.69M | 0 | Form 4 ↗ |
Landsittel Michael Chief Financial Officer | Jul 17, 2025 | D-Return | 25,000 | $54.13 | $1.35M | 0 | Form 4 ↗ |
Landsittel Michael Chief Financial Officer | Jul 17, 2025 | D-Return | 25,000 | $95.12 | $2.38M | 0 | Form 4 ↗ |
Landsittel Michael Chief Financial Officer | Jul 17, 2025 | D-Return | 22,000 | $96.57 | $2.12M | 0 | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Blueprint Medicines Corporation (BPMC) is primarily owned by institutional investors, who hold approximately 99.6% of total shares outstanding. Company insiders own approximately 7.09%, while retail and public investors account for the remaining 0.00%.
The largest institutional shareholder of Blueprint Medicines Corporation is VANGUARD GROUP INC, holding approximately 6.42 million shares — equal to 10.09% of outstanding shares — as of June 30, 2025.
A total of 381 institutional investors currently hold BPMC stock, with a combined institutional value of approximately $8.24 billion as of the most recent 13F filing period.
Frequently asked questions
BPMC ownershipBlueprint Medicines Corporation (BPMC) is primarily owned by institutional investors, who hold approximately 99.6% of shares. The largest shareholder is VANGUARD GROUP INC with a 10.09% stake. Company insiders hold 7.09%. Data sourced from SEC Form 13F as of June 30, 2025.